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Background: The performance of randomized controlled trials (RCTs) is often hindered by recruitment difficulties.
This study aims to explore the pre-screening phase of four prostate cancer RCTs to identify the impact of a
systematic pre-selection of eligible patients for RCT recruitment.
Methods: The pre-screening of four RCTs opened at the Comprehensive Cancer Center in Rennes was analyzed
retrospectively (French Genitourinary Tumor Group (GETUG) 14, 15, 16, and 17). Data were extracted from electronic
multidisciplinary cancer (MDC) reports and manually completed by physicians and medical secretaries. These data
were the main source of information for clinicians to discuss treatment alternatives during MDC sessions. The
pre-screening decisions made by the clinicians during these MDC meetings were compared with those made
after a systematic review of the MDC reports by a clinical research assistant (CRA). Any inconsistencies in decisions
between the CRA and the MDC physicians were corrected by the principal investigator (PI).
Results: The pre-screening rate was 9.1% during the MDC meetings, while it was estimated to be 12.9% after the
final review by the PI, and 29% after the systematic review by the CRA. The study showed that 77% and 67% of
the MDC reports did not mention clinical and pathological Tumor, lymph node and metastasis classification of
malignant tumors (TNM) staging, respectively, and that 35 of the CRA’s 47 proposals rejected by the PI concerned
implicit information (not specified in the MDC reports). Only one patient was proposed by the PI, and none by
the CRA.
Conclusions: These results confirm that pre-screening could be improved by a systematic review of the medical
reports. They also highlight the fact that missing data in electronic MDC reports leads to over-enrollment of
non-eligible patients, but not to over-exclusion of eligible patients. Thus, our study confirms the potential gain in
using semi-automated pre-selection of MDC reports, in order to avoid missing out on patients eligible for RCTs.
Trial registration: The trials evaluated in this study were previously registered with clinicaltrials.gov (registration
number: NCT00104741 on 3 March 2005; NCT00104715 on 3 March 2005; NCT00423475 on 16 January 2007; and
NCT00667069 on 24 April 2008).
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The randomized controlled trial (RCT) is the gold stand-
ard for evaluating the effects of healthcare procedures, but
the performance of clinical RCTs is often hindered by re-
cruitment difficulties [1]. Inadequate recruitment causes
delays, increases costs, reduces the statistical power of
analysis and finally, may lead to failed clinical trials.
Clinical trials are an important option of care for cancer
patients since they often provide the most up-to-date and
effective treatment for end-stage disease. It has also been
suggested that more participation in oncology clinical
trials could lead to improved survival in cancer patients
[2,3]. Nevertheless, patient enrollment remains particularly
low in oncology clinical trials (according to the National
Cancer Institute, less than 5% of adults with incident can-
cer participate in clinical trials in the United States) [4,5].
Barriers to recruitment for oncology clinical trials can
be summarized into three main categories [6,7]:
Individual barriers (such as patients feeling
uncomfortable with experimentation or experiencing a
loss of control over decision-making, and physician
time and effort required for recruitment),
Barriers related to RCT designs (overly strict or
non-adapted criteria, too large a number of RCTs, RCT
complexity leading to difficulties in explaining trials to
patients, and so forth), and
Barriers caused by system and organizational features
(lack of staff and research nurses, communication
difficulties, planning of local resources according to
RCT designs, and so forth).
Different strategies, often timesaving and cost-effective,
can be used to overcome these barriers (for example, hiring
a research nurse or a data manager). But there is also evi-
dence that Health Information Systems and Information
Technologies can improve the recruitment process. A re-
view of recent literature shows that many studies examine,
discuss, and/or deal with support systems for clinical trial
recruitment [5]. These are mainly concerned with address-
ing individual barriers, and sometimes with the deve-
lopment of tools to ease usability of eligibility criteria.
However, the authors highlight the lack of evaluation and
workflow integration of the support systems into the RCT
recruitment process, and they emphasize the importance of
the pre-screening phase for recruitment, particularly for
RCT recruitment systems.
In this study, we hypothesized that the improvement
of pre-screening of patients eligible for RCTs would lead
to an improvement in overall patient enrollment in cli-
nical trials. Thus, the study focused on the pre-screening
steps of patient enrollment to RCTs.
The main objective of the present study was to assess
the impact of semi-automated decision support systemsin improving patient pre-screening in oncology RCTs.
Therefore, the study compared the pre-screening deci-
sions made prospectively by the physicians during pa-
tient care, with the pre-screening decisions made with a
systematic and retrospective review of the medical re-
ports. Then, the study identified factors that could make
pre-screening more efficient.
Methods
Workflow of multidisciplinary cancer meetings
As presented in Figure 1, multidisciplinary cancer (MDC)
meetings (MDMs) are the start of patient management in
oncology and often the first step leading to patient enroll-
ment in cancer RCTs, known as the pre-screening phase.
In Brittany (France), the workflow starts with a request
made by the treating physician to the MDC secretary, in
order to schedule the presentation of the patient’s case
within the MDM (steps one and two). With the patient
data provided by the treating physician (most of the time
from the paper-based patient record), the secretary fills
in an online standard MDC report designed for each
type of cancer. The MDC report is intended to collect
all essential patient data to make the decision during the
MDM.
On the day of the MDM, the secretary shows each
MDC report to the tumor board (step three). After the
discussion, the therapeutic decision is registered (step
four) and sent back to the treating physician who can
then inform the patient.
During the MDM, some patients may be proposed (in a
pre-screening phase) as being potentially eligible for an
RCT; according to a subset of selection criteria called that
we will call ‘pre-screening criteria’. These criteria corres-
pond to those that can be checked from the retrospective
data available in the patient charts. Pre-screening criteria
include, for instance, demographic characteristics (such as
age and gender) and some medical characteristics (such
as tumor stage and surgical history). The other criteria
(which we will call ‘screening criteria’) are those that can
only be tested secondarily (in a screening phase), after
having contacted the patient (for example, a negative HIV
test on the day of enrollment). The patients are eventually
included in the appropriate RCT when all eligibility cri-
teria are met.
The present study proposes to retrospectively analyze
the decision-making process of the MDM and to com-
pare it to a systematic review of the patient’s case.
Focus on the ongoing randomized controlled trials used
for the study
Urologic oncology was chosen as the experimental field
for practical reasons, partly because most eligibility cri-
teria are readily handled by computerized data (Tumor,
lymph node and metastasis classification of malignant
Figure 1 The therapeutic decision-making process for patients with cancer in Brittany (France), including the multidisciplinary cancer
(MDC) meeting. Step one: MDC meeting request by a treating physician concerning a patient; step two: MDC meeting scheduled by the MDC
secretary; step three: presentation of the MDC report during the MDC meeting; step four: registration of the therapeutic decision in the oncologic
electronic health records (EHR) and feedback to the treating physician.
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specific antigen (PSA) level, and so forth). The study fo-
cused on prostate cancer, which is the most common
form in urology. It is also the main topic of discussion at
urology MDMs and of many clinical trials.
Four prostate cancer clinical trials were active and recrui-
ting patients at the Cancer Research Institute of Rennes
during the study period (between October 2008 and
March 2009), all conducted by the French Genitourinary
Tumor Group (GETUG) [8]:
 GETUG 14, comparing triptorelin, flutamide, and
external-beam radiation therapy to external-beam
radiation therapy alone in treatment of patients with
stage II or stage III prostate cancer (Clinicaltrials.gov
identifier: NCT00104741);
 GETUG 15, comparing hormone therapy and
docetaxel to hormone therapy alone in treatment of
patients with metastatic prostate cancer
(Clinicaltrials.gov identifier: NCT00104715);
 GETUG 16, comparing radiation therapy and
goserelin to radiation therapy alone in treatment of
patients who have undergone surgery for recurrent
or refractory prostate cancer (Clinicaltrials.gov
identifier: NCT00423475); GETUG 17, comparing immediate triptorelin and
radiation therapy after surgery to the delayed
treatment of patients who have undergone surgery
for intermediate-risk stage III or stage IV prostate
cancer (Clinicaltrials.gov identifier: NCT00667069).
Detailed eligibility criteria for the four RCTs discussed
at the MDMs during the study period are presented in
Table 1. The RCTs were conducted in accordance with
the Declaration of Helsinki. All participants were re-
quired to give written informed consent before enroll-
ment in one of the four studies.
Data collection
The data used in our study consisted of the information
contained in the MDC reports, and of the corresponding
therapeutic decisions taken during the MDMs. The
MDC reports included general characteristics of pa-
tients, medical history, and data related to prostate can-
cer, such as the Gleason score, tumor staging (clinical
and pathological TNM classification), and the prostate-
specific antigen (PSA) level. According to each case, the
MDC team’s decisions were either to propose a standard
therapy to the patient, or to participate in a clinical trial
(in this case, the MDC team had estimated that pre-
Table 1 Eligibility criteria of GETUG 14, GETUG 15, GETUG 16, and GETUG 17 clinical trials
Eligibility
criteria
GETUG 14 (NCT00104741) GETUG 15 (NCT00104715) GETUG 16 (NCT00423475) GETUG 17 (NCT00667069)
Disease
characteristics
Histology Histologically confirmed prostate
cancer: (Stage T1b-T1c AND PSA
≥10 ng/mL) OR (Stage T1b-T1c









(or pT4 by reaching the bladder
neck), or R1 disease, OR pN0 or pNxa
Disease’s prior
treatment
Not specified Not specified Treated with surgery onlya Treated by curative surgery in the
past 6 monthsa
Positive margins (tumoral glands in
contact with contour ink)
Metastasis No metastatic disease (M0)
confirmed by thoracic
radiography and bone scana




History of invasive cancera Brain metastasesa Clinical signs of progressive disease pN1 disease, pT2 disease,




PSA <30 ng/mL Not specified PSA ≤0.1 ng/mL after
prostatectomya
PSA ≤0.1 ng/mL after
prostatectomya





Age Under 75a 18 and overa 18 and overa 18 and overa
Performance
status
ECOG 0-1a ECOG 0-2a ECOG 0-1a ECOG 0-1a
Life
expectancy
At least 10 yearsa At least 3 monthsa ≥10 yearsa ≥10 yearsa




Hepatic Not specified Bilirubin ≤1.5 × upper limit of
normal (ULN) AND AST, ALT
≤1.5 × ULN
Not specified Not specified
Renal Not specified Creatinine ≤150 μmol/L Not specified Not specified
Cardiovascular Not specified No symptomatic coronary
diseasea
No uncontrolled hypertension No uncontrolled hypertension
No congenital cardiac
insufficiencya
(systolic ≥160, diastolic ≥90 mm Hg) (systolic ≥160, diastolic ≥90 mm Hg)













Table 1 Eligibility criteria of GETUG 14, GETUG 15, GETUG 16, and GETUG 17 clinical trials (Continued)
Other diseases Not specified No other malignancy (in the past
5 years)a
No other malignancy (in the past
5 years)a
No other malignancy (in the past
5 years)




No contraindication of intramuscular
injectiona
Other Not specified No compliance and follow-up
difficulties due to familial, social,
geographical, or psychological
situationa
No compliance and follow-up diffi-
culties due to familial, social, geo-
graphical, or psychological situationa
No compliance and follow-up
difficulties due to familial, social,
geographical, or psychological
situationa
Affiliated with social security
programa
Affiliated with social security
programa
No patients who are deprived of




Chemotherapy Not specified No prior chemotherapy for
metastatic prostate cancer
(within the past year)a
Not specified Not specified
Endocrine
therapy
No prior hormonal therapya Prior hormonal therapy within
the past 2 months alloweda
No prior hormonal therapya No prior hormonal therapya
Radiotherapy No prior pelvic radiotherapya No prior radiotherapy to
metastatic sites (within the 4 last
weeks) a
No prior pelvic radiotherapya No prior radiotherapy within
3 months after radical
prostatectomya
No prior pelvic radiotherapya
Surgery No prior radical prostatectomya No prior surgical castrationa No prior surgical or chemical
castrationa
No prior surgical or chemical
castrationa
No prior castration At least 6 months since surgery for
biological recurrencea
Other Not specified No concurrent investigational
drugsa
No concurrent anticancer therapya No concurrent participation in
another studya
aeligibility criterion available for pre-screening; pTNM: pathological Tumor Nodes and Metastasis staging; PSA: Prostate-specific antigen; ECOG: Eastern Cooperative Oncology Group (ECOG) Performance status;
WBC: White Blood Cell; ULN: Upper limit of normal; AST: aspartate aminotransferase (i.e. SGOT: serum glutamic oxaloacetic transaminase); ALT: alanine aminotransferase (i.e. SGPT: serum glutamic-pyruvic transaminase);
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and MDM decisions were retrospectively and exhaustively
collected. The data extraction (Figures 1 and 2) corre-
sponded to a period of six months while patient recruit-
ment for the four prostate cancer RCTs was occurring.
Data were completed with the number of medical re-
cords and the number of prostate cancer records dis-
cussed at each MDC meeting, as well as the number of
physicians who participated in the MDMs.
Ethical statement
The local ethics committee, ‘Comité d’éthique du CHU
de Rennes’, approved the present study (registration
identifier: 13–26). All four trials cited in this study ob-
tained ethical approval by a research ethics committee
with the following approval numbers for GETUG 14:
2003/015 (CPPRB Haute Normandie), for GETUG 15:
04/08 (CPPRB Marseille 1), GETUG 16: 06/025 (CPPRB
Lyon), GETUG 17: 2007/53 (CPP Sud-Ouest et Outre
Mer III).
Evaluation and statistical analysis
The evaluation protocol consisted in collecting and com-
paring three types of decision (MDC, clinical research
assistant (CRA), and principal investigator (PI)). The
MDC team’s decision was the initial tumor board’s deci-
sion made directly during the MDM.Figure 2 Evaluation design of the multidisciplinary cancer (MDC) team
from the oncologic electronic health records (her); step two: Extraction of t
3: systematic review of the MDC reports by the clinical research assistant (C
CRA and the MDC team; step five: principal investigator’s review of the MD
decisions and the MDC team’s decisions; step six: final pre-screening decisiThe CRA’s decision (Figure 2, step three) was obtained
by asking a CRA experienced in recruitment to clinical
trials to systematically review all the MDC reports (while
ensuring to hide the MDC team’s decision). Thus, the
CRA only had access to information explicitly contained
in the MDC reports; the CRA did not have any know-
ledge or information about the patients other than MDC
reports and was unaware of MDC decisions. The MDC
decisions and CRA’s decisions were compared (Figure 2,
step four). A PI reviewed the MDC reports correspon-
ding to the discrepancies between the CRA’s decisions
and MDM decisions (Figure 2, steps five and six). In our
study, we considered the PI’s decision (Figure 2, step six)
as being the best gold standard as the PI is the person
the most involved in clinical trial recruitment.
Results were described using means associated with
standard deviations (m± ε), and absolute and relative fre-
quencies (n (%)). The MDC, CRA, and PI pre-screening
decisions were described especially by the MDC, CRA
and PI pre-screening rate, and compared using the McNe-
mar’s chi-square test. Factors that could influence the
MDC team’s pre-screening decisions (the characteristics
of the MDMs and the content of the MDC reports) were
tested using the Pearson’s correlation test and the Mann–
Whitney U test.
A descriptive analysis of the discrepancies between
the MDC, CRA, and PI proposals was also performed.’s pre-screening decisions. Step one: extraction of the MDC reports
he MDC team’s pre-screening decisions from the oncologic EHR; Step
RA); step four: comparison of the pre-screening decisions made by the
C reports corresponding to the discrepancies between the CRA’s
ons (gold standard) including the principal investigator’s decisions.
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Foundation for Statistical Computing, Vienna, Austria
[9]. Two-tailed P values were reported with P <0.05 con-
sidered to be statistically significant.
Results
Description of the multidisciplinary cancer meetings and
the multidisciplinary cancer reports
During the study period, 23 urologic MDMs were held
at the Comprehensive Cancer Center of Rennes, and 466
MDC reports were analyzed. Among them, 286 MDC
reports concerned patients with prostate cancer, all of
which were evaluated in the present study.
On average, 7 ± 1.7 physicians, including 3 ± 0.9 on-
cologists, attended each MDM. The PI of GETUG 14
was present at 12 of the 23 MDMs held during the study
period, the PI of GETUG 15 at 15 of the 23 MDMs, the
PI of GETUG 16 at 12 of the 23 MDMs, and the PI of
GETUG 17 at 13 of the 23 MDMs.
On average, during an MDM, 20 ± 6.2 reports were
discussed with 12 ± 4.6 of those being related to patients
with prostate cancer. Clinical and pathological TNM
stages were found in 67 (23.4%) and 94 (32.9%) of the
286 MDC reports, respectively concerning patients with
prostate cancer. However, 261 (91.3%) and 252 (88.1%)
of the 286 MDC reports included the Gleason score and
the PSA level, respectively.
Factors influencing the MDC team’s pre-screening
decisions in GETUG 14, 15, 16 and 17
A total of 26 patients were proposed for screening by
the physicians who participated in the MDMs; 17 for
screening in GETUG 14, seven for screening in GETUG
16 and two for screening in GETUG 17. No patient was
proposed for screening in GETUG 15.
Among factors that may have influenced pre-screening
during the MDMs (the MDC team’s decisions), a sta-
tistically significant and negative correlation was found
between the number of MDC reports concerning pa-
tients with prostate cancer and the pre-screening rate of
each MDM (Pearson correlation coefficient (r) = −0.42,
P = 0.046). There was also a reverse correlation between
the overall number of MDC reports discussed in MDMs
and the pre-screening rates of the MDMs, but thisTable 2 Results of pre-screening of patients eligible for the cl
GETUG 17
GETUG 14 GETUG 15
MDC team’s decisions (1) 17 (5.9%) 0
CRA’s decisions (2) 59 (20.6%) 8 (2.8%)
PI’s decisions (3) 30 (10.5%) 0
*McNemar’s chi-squared test: (1) versus (2) P <10−3; (1) versus (3) P = 0.022; (2) versu
(1) Decisions of the physicians during the multidisciplinary cancer (MDC) meetings;
the MDC reports; (3) Final decisions after the principal investigator (PI) corrected thnegative correlation was not found to be significant
(r = −0.37, P = 0.082). The number of physicians and the
number of oncologists attending the MDMs did not sig-
nificantly influence the pre-screening rates (P = 0.521
and P = 0.964, respectively). Neither did the presence of
the PI, whatever the RCT (GETUG 14: P = 0.095,
GETUG 15: no initial pre-screening proposal, GETUG
16: P = 0.550, GETUG 17: P = 0.950).
Absence of (clinical and pathological) TNM staging,
the Gleason Score, or the PSA level in the MDC reports
did not hinder MDM attenders to make pre-screening
decisions, and did not significantly influence the pre-
screening rate of the MDC team (data not shown).
Pre-screening rates based on the multidisciplinary cancer
team’s, clinical research assistants, and PI’s decisions
In total, 146 cumulative MDC report selections were re-
corded, concerning 86 different patients eligible for at least
one RCT. GETUG 14 was the RCT with the most selec-
tions during the pre-screening period, with 106 (72.6%)
proposals concerning 60 (69.8%) different patients. Pre-
screening rates related to each RCT, according to the MDC
team’s, CRA’s, and PI’s decisions, are reported in Table 2.
The overall pre-screening rates were estimated at 9.1% (26
patients) based on the MDC decisions, 29.0% (83 patients)
based on the CRA’s decisions, and 12.9% (37 patients) based
on the PI’s decisions.
A total of 22 patients were found eligible for screening
in an RCT based on at least two pre-screening methods;
most pre-selections were for the same RCTs. Only one
discrepancy was observed between decisions made at the
MDM and the CRA (GETUG 17 versus GETUG 16, re-
spectively), but the PI retained neither.
Discrepancies mainly concerned patients initially ex-
cluded during the MDC meetings (59 patients were pro-
posed by the CRA and 14 were finally validated by the PI).
Regarding patients initially proposed for an RCT during
the MDC meetings, two patients were secondarily ex-
cluded by the CRA and, finally, the PI definitively excluded
four patients. There was no patient who was not proposed
by the CRA but was proposed either during an MDM or
by the PI. Nevertheless, the PI proposed one patient who
was not proposed either by the CRA or at the MDC mee-
tings. Figure 3 summarizes these results in aVenn diagram.inical trials GETUG 14, GETUG 15, GETUG 16, and
GETUG 16 GETUG 17 Total*
7 (2.4%) 2 (0.7%) 26 (9.1%)
13 (4.5%) 3 (1.0%) 83 (29.0%)
6 (2.1%) 1 (0.3%) 37 (12.9%)
s (3) P <10−3.
(2) Decisions of a clinical research assistant (CRA) after the systematic review of
e discrepancies between the MDC team’s and the CRA’s decisions.
Figure 3 Venn diagram of the pre-screening of patients eligible for four randomized clinical trials carried out at the Comprehensive
Cancer Center in Rennes (GETUG 14, 15, 16, and 17). Pre-screening was based on the physicians’ decisions during the multidisciplinary cancer
meetings (MDC team’s decisions), the decisions of the clinical research assistant (CRA’s decisions), and the principal investigator (PI’s decisions)
after a systematic review of the MDC reports.
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PI were due to mistakes on the evaluation of some
exclusion criteria during the MDMs (too high a PSA rate
or the presence of a positive margin after surgery).
Among the CRA's 47 pre-selections that were not
retained by the PI, 35 were due to implicit information
known only by the clinicians and not explicitly available
in the MDC reports. For example, the PI excluded 18
CRA proposals because the patients had a Gleason score
of less than seven, but such a criterion was not described
in the exclusion or inclusion criteria of the RCTs. In the
same way, six patients could have been eligible for an
RCT but the MDC teams judged another type of care
more effective. Further, nine patients were excluded be-
cause they had some specific characteristics (vital status,
combination of comorbidities, and wishes) not compa-
tible with enrollment in the RCTs according to the
MDC teams.
Discussion
In this study, the pre-screening rate with MDC team’s
decisions made during the MDMs was estimated to be
at 9.1%. It is higher than rates previously reported in
other studies (around 5% for oncology RCTs) [4]. Never-
theless, the best pre-screening rate was estimated to be
12.9% (based on the PI’s decisions). This confirms that
patient pre-screening in clinical cancer research couldbe improved by a systematic review of the MDC reports
after MDMs.
It has been shown that individual barriers, such as the
time and effort required for patient recruitment for the
physicians, are factors that decrease enrollment in RCTs
[6]. The present study found that all patients proposed by
the PIs were also proposed by the CRA’s systematic re-
view, except one. In other words, the CRA’s review re-
sulted in the justified rejection of more than 200 of the
286 initial MDC reports. Thus, we argue that the addition
of a manual (or a computerized) systematic review at the
first step of the screening process (the pre-screening
phase) could lead to substantial gains in time and effort
for the physicians’ screening task afterwards.
Nevertheless, the results showed that the pre-screening
decision should not be based only on the information
available in the MDC reports, since some data are missing
(such as TNM staging), or are not explicit. These issues
illustrate why the pre-screening rate (29.0%) is so high
when the CRA makes the decision alone; because their de-
cision relies only on the content of the MDC reports.
Missing data cannot be used to exclude the patients who
are then selected as being eligible for RCTs. From the per-
spective of automating this decision-making process using
a recruitment support system, we can foresee that such a
system will overestimate the number of patients poten-
tially eligible for RCTs, just as the CRA has done.
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not intended to replace the physicians’ decision, but to
help physicians by reminding them that every patient is
potentially eligible for an available clinical trial. The
main objective will therefore be more to avoid missing
out on patients who could be included than deciding
which patients should be included.
Indeed, our result showed that clinical TNM staging
and pathological TNM staging are missing in 68% and
76%, respectively, of the MDC reports proposed by pre-
screening after correction by the PI (data not shown).
From a decision-making perspective, missing and impli-
cit data (only known by the physicians of the MDC
teams) could be seen as problematic regarding patient
selection, but our results showed that missing and impli-
cit information usually led to the exclusion of patients.
Thus, these results showed that missing and implicit
data mainly caused an overestimation of patients eligible
for RCTs, resulting in the decreased precision of the sys-
tematic (or automated) pre-screening, but this did not
lead to the wrongful exclusion of eligible patients.
It could be argued that observations in the present
study reflect local patterns of pre-screening practice and
medical record design. Indeed, centers with routine sys-
tematic pathology reporting, in line with international
standards, could certainly have a better registration rate
of clinical and pathological TNM staging and thus in-
crease the performance, and above all precision, of sys-
tematic (or automated) pre-screening.
This illustrates that the best pre-screening practices
cannot be guaranteed without providing the essential in-
formation (such as TNM staging) at the time of pre-
screening, but they are not limited due to the systematic
(or automated) pre-screening methods themselves. The
present study shows that despite the presence of numer-
ous missing data concerning key elements for enroll-
ment in RCTs in urologic oncology, the implementation
of a manual (or a computerized) systematic review could
optimize the pre-screening task by improving the pre-
screening rate and by reducing the time and effort re-
quired for pre-screening by physicians.
We did not succeed in discovering which factors could
really impact the pre-screening rate, except for the number
of MDC reports discussed per session. The low number of
patients who are actually eligible in the present study could
be a limit to the interpretation of such a result, but it
confirmed at least that the workload during the MDC
meetings is a major factor that decreases pre-screening
performance and enrollment in RCTs in oncology. There-
fore, this is a strong argument for research as investigated
in the automatic selection of clinical trials based on eligi-
bility criteria (ASTEC) project [10], which aims to provide
tools to physicians (oncologists) to make the recruitment
of patients for RCTs easier and more automatic.Conclusions
The study found that a systematic review of medical re-
ports could increase the cumulative pre-screening rates
of four RCTs recruiting patients at the Comprehensive
Cancer Center in Rennes from 9 to 13%. Also, we argue
that such an additional systematic review during the first
step of the screening process could lead to substantial
gains in time and effort for physicians in their task of
recruiting patients for RCTs.
The study also showed that missing data in the MDC
reports leads to a systematic review that over-includes
non-eligible patients, but does not over-exclude eligible
patients. Therefore, we confirm the potential gain in using
the semi-automated selection of electronic MDC reports
to avoid missing out on patients eligible for RCTs.
To conclude, optimizing the pre-screening process rep-
resents an interesting way to improve patient enrollment
in clinical trials, which remains particularly low in on-
cology research. The use of computerized pre-screening
support systems to perform a systematic review of eligible
patients could help to reach such an objective.
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